S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Autolus Therapeutics (AUTL) Stock Forecast, Price & News

+0.04 (+1.55%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
194,847 shs
Average Volume
328,514 shs
Market Capitalization
$238.18 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AUTL News and Ratings via Email

Sign-up to receive the latest news and ratings for Autolus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Autolus Therapeutics logo

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.


Autolus Therapeutics Q1 2022 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$2.33 million
Book Value
$2.98 per share


Net Income
$-142.10 million
Net Margins
Pretax Margin




Free Float
Market Cap
$238.18 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.04 out of 5 stars

Medical Sector

540th out of 1,424 stocks

Biological Products, Except Diagnostic Industry

86th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Autolus Therapeutics (NASDAQ:AUTL) Frequently Asked Questions

Is Autolus Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Autolus Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Autolus Therapeutics stock.
View analyst ratings for Autolus Therapeutics
or view top-rated stocks.

When is Autolus Therapeutics' next earnings date?

Autolus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Autolus Therapeutics

How were Autolus Therapeutics' earnings last quarter?

Autolus Therapeutics plc (NASDAQ:AUTL) posted its quarterly earnings results on Thursday, May, 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.10. The firm earned $0.17 million during the quarter, compared to analysts' expectations of $0.26 million. Autolus Therapeutics had a negative net margin of 6,551.06% and a negative trailing twelve-month return on equity of 52.44%. During the same quarter last year, the business earned ($0.53) EPS.
View Autolus Therapeutics' earnings history

What price target have analysts set for AUTL?

4 equities research analysts have issued 1 year price objectives for Autolus Therapeutics' stock. Their forecasts range from $11.00 to $18.00. On average, they expect Autolus Therapeutics' share price to reach $13.67 in the next twelve months. This suggests a possible upside of 421.6% from the stock's current price.
View analysts' price targets for Autolus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Autolus Therapeutics' key executives?
Autolus Therapeutics' management team includes the following people:
  • Dr. Christian Martin Itin Ph.D., CEO & Director (Age 58, Pay $2.47M)
  • Dr. Martin Pule M.D., MBBS, Founder, Sr. VP & Chief Scientific Officer (Age 50)
  • Mr. Christopher Vann, Sr. VP & COO (Age 57)
  • Mr. David Brochu, Sr. VP & Chief Technical Officer (Age 66)
  • Mr. Andrew J. Oakley ACA, BEcon, MBA, Sr. Advisor (Age 60)
  • Mr. Brent Rice, Sr. VP & Chief Commercial Officer (Age 56)
  • Dr. Edgar E. W. Braendle M.D., Ph.D., Sr. VP & Chief Devel. Officer (Age 62)
  • Dr. Lucinda Crabtree Ph.D., Chief Financial Officer
  • Dr. Chris Williams, Sr. VP of Corp. Devel. (Age 42)
  • Mr. Alexander Swan, Sr. VP, HR & Internal Communications
What other stocks do shareholders of Autolus Therapeutics own?
When did Autolus Therapeutics IPO?

(AUTL) raised $125 million in an initial public offering on Friday, June 22nd 2018. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and Wells Fargo Securities and William Blair were co-managers.

What is Autolus Therapeutics' stock symbol?

Autolus Therapeutics trades on the NASDAQ under the ticker symbol "AUTL."

Who are Autolus Therapeutics' major shareholders?

Autolus Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (4.78%), Frazier Life Sciences Management L.P. (4.12%), Pendal Group Ltd (1.51%), Capital World Investors (1.17%), JPMorgan Chase & Co. (0.88%) and Woodline Partners LP (0.88%).

Which major investors are selling Autolus Therapeutics stock?

AUTL stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Woodline Partners LP, BlackRock Inc., State Street Corp, Pendal Group Ltd, JPMorgan Chase & Co., Harbor Capital Advisors Inc., and Eversept Partners LP.

Which major investors are buying Autolus Therapeutics stock?

AUTL stock was acquired by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., LGT Capital Partners LTD., Deep Track Capital LP, Nantahala Capital Management LLC, Goldman Sachs Group Inc., UBS Group AG, Privium Fund Management B.V., and Moloney Securities Asset Management LLC.

How do I buy shares of Autolus Therapeutics?

Shares of AUTL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Autolus Therapeutics' stock price today?

One share of AUTL stock can currently be purchased for approximately $2.62.

How much money does Autolus Therapeutics make?

Autolus Therapeutics has a market capitalization of $238.18 million and generates $2.33 million in revenue each year. The company earns $-142.10 million in net income (profit) each year or ($1.860010) on an earnings per share basis.

How many employees does Autolus Therapeutics have?

Autolus Therapeutics employs 324 workers across the globe.

What is Autolus Therapeutics' official website?

The official website for Autolus Therapeutics is www.autolus.com.

How can I contact Autolus Therapeutics?

Autolus Therapeutics' mailing address is FOREST HOUSE 58 WOOD LANE WHITE CITY, LONDON X0, W12 7RZ. The company can be reached via phone at 442038296230 or via email at [email protected].

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.